<DOC>
	<DOCNO>NCT02590939</DOCNO>
	<brief_summary>The main objective study assess efficacy Cefaly® device acute treatment migraine attack adult patient . The patient apply either active placebo external neurostimulation 1 hour migraine attack , report pain visual analog scale treatment .</brief_summary>
	<brief_title>Randomized Controlled Trial Acute Treatment Migraine With Cefaly® Device</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>History episodic chronic migraine without aura meeting diagnostic criterion list ICHDIII beta ( 2013 ) section 1 , migraine , exception `` complicate migraine '' ( i.e. , hemiplegic migraine , basilartype migraine , ophthalmoplegic migraine , migrainous infarction ) Having migraine attack last least 3 hour Migraine pain intensity stabilize least 1 hour Frontal , retro , peri orbital headache . Pregnant woman Patients receive Botox treatment prior 4 month Patients receive supraorbital nerve block prior 4 month Diagnosis primary secondary headache disorder , except Medication Overuse Headache Patients temporal occipital headache Patients use opioid medication Patients take abortive migraine medication prior 3 hour Allodynia : intolerance supraorbital neurostimulation ( allodynia ) make treatment applicable ( patient exclude unable tolerate first 5 minute neurostimulation ) . Implanted metal electrical device head Cardiac pacemaker implant wearable defibrillator Patient previous experience Cefaly®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>